You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Article Text

Article menu

See original article:

Download PDFPDF

XML
Correction
Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
  1. Vaia Florou1,a,
  2. Andrew E. Rosenberg1,
  3. Eric Wieder1,
  4. Krishna V. Komanduri1,
  5. Despina Kolonias1,
  6. Mohamed Uduman2,
  7. John C. Castle2,
  8. Jennifer S. Buell2,
  9. Jonathan C. Trent1 and
  10. Breelyn A. Wilky1
  1. 1 0000 0004 1936 8606grid.26790.3aDepartment of Medicine, Division of OncologySylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine 1475 NW 12th Avenue 33136 Miami FL USA
  2. 2 0000 0004 0486 2652grid.420152.0Agenus Inc. 3 Forbes Road 02421 Lexington MA USA
  1. ↵a vaia.florou{at}hsc.utah.edu

Abstract

Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”.

The original article can be found online at 10.1186/s40425-019-0689-7

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

https://doi.org/10.1186/s40425-019-0792-9

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The original article can be found online at 10.1186/s40425-019-0689-7

    Correction to: J ImmunoTher Cancer

    https://doi.org/10.1186/s40425-019-0689-7

    Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells.”

    should be replaced with

    “Ipilimumab and AGEN1884 are IgG1 class antibodies. AGEN1884 data show CTLA-4 inhibition and activity against T regulatory cells (reference 8).”

    Reference

    1. 1.↵
      2. Florou , et al
      . Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J ImmunoTher Cancer. 2019;7:213 doi:10.1186/s40425-019-0689-7 pmcid:6686562
      OpenUrlAbstract/FREE Full Text